Send to

Choose Destination
Curr Opin Pharmacol. 2017 Dec;37:112-117. doi: 10.1016/j.coph.2017.10.013. Epub 2017 Nov 10.

Pharmacological management of gastroesophageal reflux disease in infants: current opinions.

Author information

Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, USA.
College of Pharmacy, Helwan University, Cairo, Egypt.
Divisions of Neonatology and Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA. Electronic address:


Gastroesophageal reflux disease (GERD) constitutes a troublesome symptom complex resulting from retrograde passage of gastric contents into the esophagus or extra-esophageal regions. Premature-born, high-risk infants and those with neuro-aero-digestive pathologies are at increased risk. Critical review over the last 3 years was conducted, and current opinions on pharmacological targets include agents aimed at prevention of transient lower esophageal sphincter relaxation, modification of the physico-chemical composition of gastric contents, modification of gut motility, or altering sensory thresholds to ameliorate the troublesome symptoms. As data from well-designed studies is limited in the infant population, information from adult studies has been cited where potential application may be helpful.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center